Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P01275 (glucagon)
 26,492 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

In two groups of healthy men the dynamics of left-ventricular contraction was studied by Weissler's method based on synchronous recording of ECG, phonocardiogram and carotid sphygmogram. Group I comprised 20 subjects in whom this recording was performed during maximal exercise and 90-minute restitution (1 W/kg/6 min, 2 W/kg/6 min, 3 W/kg/6 min). Group II (n = 17) performed the same exercise immediately after intravenous injection of glucagon 50 micrograms/kg of body weight. Glucagon administration before the exercise reduced the functional reserve of the left ventricle during the exercise impairing the pumping action of the left ventricle during the restitution. After glucagon administration the restitution of left-ventricular contraction periods was characterized by decreased value of the ejection time index (LVETI), prolonged pre-ejection period (PEP), isovolumetric contraction time (ICT), and diminished LVET/PEP index in relation to the values obtained at the same time in the control group (p less than 0.05). Glucagon caused no changes in the exercise tolerance of the studied subjects and had no effect on the time of postexercise restitution.
Acta Physiol Pol
PMID:Effect of exogenous glucagon on left-ventricular contraction dynamics during restitution after exercise in healthy men. 718 May 23

The contribution of major gastrointestinal hormones to bile secretion was studied in 35 male Wistar rats with biliary, duodenal, and vena cava cannulae. Intravenous infusion of secretin, pancreozymin, and glucagon increased bile flow but only secretin affected bile lipid output. OP-CCK exerted the weakest choleretic effect. None of the hormones significantly changed the lithogenic index. Thus, gastrointestinal hormones could play an important role in the regulation of bile flow and bile lipid secretion in rats.
Acta Physiol Pol
PMID:The effect of gastrointestinal hormones on bile flow, bile lipid composition, and lithogenicity in rats. 718 20

The aim of the study was to investigate whether oral application of misoprostol (MI), which is an analogue of prostaglandin E1, does change the secretion of insulin and the blood glucose level. The investigations were carried out in 15 subjects, aged 21-40 yrs, with a gastric or duodenal ulcer and without any disturbances of the digestive tract motility. In 7 of them (group A), without stated diabetes a single oral dose of 400 mg MI versus placebo (PL) and 15 min later 75 g glucose p.o., was applied in randomized order, on different days, in fasting state. In 8 subjects with mild diabetes type II (gr B) MI versus PL and after 15 min. i.v. 1.0 mg glucagon was similarly administered. In both groups the concentrations of glucose and C-peptide in blood were determined. In comparison to PL, the application of MI did not cause any statistically significant differences of C-peptide in serum and blood glucose levels neither before and after oral glucose loading nor after i.v. administration of glucagon. Statistically not significant were also the differences in AUC (p > 0.05).
Pol Arch Med Wewn 1994 Aug
PMID:[Effect of misoprostol, a synthetic prostaglandin E analog, on levels of serum C-peptide in serum and glucose tolerance]. 780 May 81

As shown in our previous study, hypothermia provokes a variety of hormonal changes including inhibition of insulin secretion and increase in blood serum glucagon level. According to Therminarias et al. the administration of exogenous insulin to dogs subjected to hypothermia causes a calorigenic effect by enhancing oxygen consumption and rising the intensity of shivering thermogenesis. The study was aimed at establishing whether exogenous insulin administered to rats subjected to brief hypothermia and having the shivering thermogenesis blocked by thiobutabarbital anesthesia can influence rectal temperature, the levels of some hormones and energy metabolism. The results obtained suggest that 1) insulin administration causes an increase in the energy charge potential (ECP) both in the liver and in skeletal muscle of the rat, indicating the domination of anabolic processes both in normothermic and hypothermic conditions, 2) there is a negative correlation between the levels of insulin and free fatty acids and the activity of isocitric dehydrogenase in rat liver mitochondria, and 3) the administration of insulin at a dose provoking metabolic response both in normothermic and hypothermic conditions was ineffective in provoking temperature response, indicating the existence of a functional dissociation between the various effects of the same dose of exogenous insulin.
Endokrynol Pol 1993
PMID:[Effect of insulin on temperature and metabolic responses in rats during normothermia and hypothermia]. 805 Mar 87

The concentrations of beta-endorphin, ACTH, insulin (IRI), glucagon (IRG), cortisol and growth hormone were determined by radioimmunoassay during oral glucose tolerance test (OGTT) performed in 13 obese patients with normal glucose tolerance and without arterial hypertension. The test was performed in random, before and after intravenous administration of 0.8 mg of naloxone. Six persons with normal body weight served as controls. Higher basal concentrations of beta-endorphin and significant increase in beta-endorphin levels during OGTT, without concomitant increase in ACTH concentrations, have been found in obese patients. No effect of naloxone on beta-endorphin liberation during OGTT was observed, though the drug caused lowering in maximal increment of beta-endorphin and paradoxically lowered the concentrations of ACTH and cortisol. The basal concentrations of beta-endorphin did not correlate with the concentrations of insulin, ACTH, cortisol and growth hormone. Elevated concentrations of insulin, lowered concentration of growth hormone and normal levels of glucose and glucagon were observed in basal conditions, and excessive responses of insulin, glucose and glucagon were observed in obese patients during OGTT. Naloxone lowered insulin response and inhibited the fall of growth hormone during OGTT but did not influence the concentrations of glucose and glucagon. No correlation was found during OGTT after naloxone between insulin and beta-endorphin, ACTH or cortisol, whereas negative correlation was observed between insulin and growth hormone. The obtained results suggest that the elevated concentrations of beta-endorphin in simple obesity may be of both hypophyseal and peripheral origin. Hyper-beta-endorphinemia observed in obesity is probably not directly responsible for hyperinsulinemia, it may, however, be responsible for lower sensitivity of tissues to the action of insulin.
Endokrynol Pol 1993
PMID:[Effect of naloxone on beta-endorphin and insulin concentrations during glucose tolerance testing in patients with simple obesity]. 805 20

Pancreatic glucagon plasma concentration (IR-G) were measured during oral glucose tolerance test (GTT) in workers exposed to whole body vibration and noise. In workers with abnormal GTT higher IR-G concentrations were found in comparison with the control group. Langerhans islet alfa cells stimulation may be responsible for a higher frequency of elevated glycemia during GTT in workers exposed to whole body vibration and noise.
Pol Arch Med Wewn 1994 Apr
PMID:[Plasma pancreatic glucagon during glucose tolerance test in workers exposed to vibration and noise]. 807 86

An effect of nonselective beta-adrenergic blockade with propranolol on the blood plasma level of glucagon during insulin-induced hypoglycemia was studies in 20 control dogs and 20 alloxan diabetic dogs. Increased sensitivity to exogenous insulin and prolonged hypoglycemia were noted during nonselective beta-adrenergic blockade. However, glucagon response to insulin-induced hypoglycemia following propranolol administration was increased.
Pol Tyg Lek
PMID:[Effect of nonselective beta-adrenergic blockade on blood plasma levels of glucagon in plasma during insulin-induced hypoglycemia]. 836 79

Secretion of insulin, glucagon, gastrin and pancreatic polypeptide (PP) at basal and test meal stimulation conditions were investigated in 17 patients with essential hypertension (EH) before and after 12 months of treatment with prazosin and in 10 healthy subjects. Before prazosin therapy, patients with EH differ from healthy subject higher insulin and gastrin but lower PP secretion after test meal stimulation. 12 month therapy with prazosin enhanced insulin and suppressed gastrin secretion stimulated by test meal in comparison to the pretreatment values. Prazosin therapy did not influence significantly glucagon and PP secretion. Our results suggest, that long term prazosin treatment markedly influenced insulin and gastrin secretion in patients with EH.
Pol Arch Med Wewn 1993 Jan
PMID:[Effect of long term prazosin treatment on secretion of insulin, glucagon, gastrin, and pancreatic polypeptide in patients with essential hypertension]. 847 41

The study aimed to assess the influence of long-term rhuEPO treatment on secretion of pancreatic hormones (insulin, glucagon). A total of 27 haemodialyzed and 9 healthy subjects were examined. Nine patients with uraemic anaemia were treated with rhuEPO for 12 months (EPO group) while another nine patients did not receive rhu-EPO (non-EPO group), but were monitored biochemically and clinically as patients of the EPO group. The third group (HD) comprised nine haemodialyzed patients with a haematocrit value of > 30%, without rhu-EPO therapy. In all subjects plasma levels of glucose, insulin (IRI) and glucagon (Glu) were estimated before and after administration of the test meal. Patients of the EPO and non-EPO group were examined before and after 6 and 12 months of rhu-EPO treatment (EPO group) or clinical monitoring (non-EPO group) respectively, while only one test was performed in patients of the HD group and healthy subjects. During the observation period fasting glicaemia did not change. Six months of rhu-EPO therapy was followed by an increase of fasting insulinaemia and decrease of basal plasma level of glucagon. At that time point rhu-EPO therapy also increased the response of IRI and Glu to the test meal and the insulin/glucose index. After 12 months of rhu-EPO therapy basal insulinaemia and insulin/glucose index returned to the pretreatment value while plasma level of glucagon and the response to the test meal were lower than pretreatment one. Our results suggest that rhu-EPO treatment exerts a profound effect on carbohydrate metabolism and secretion of IRI. Glu, which seems to be dependent upon duration of rhu-EPO therapy and not only, or exclusively to improvement of the haematological status.
Pol Arch Med Wewn 1995 Dec
PMID:[Influence of long-term treatment with human recombinant erythropoietin on secretion of hormones regulating carbohydrate metabolism in hemodialyzed patients with chronic uremia]. 861 11

The aim of the study was to evaluate glucose tolerance, B cell secretion and hepatic clearance of insulin during the process of aging. 100 subjects of both sexes, in age range of 17 to 92 years and with BMI < 27 kg/m2 were studied. All subjects were divided in 4 groups according to age: 18 patients were in age from 17 to 59 years (group I--mean 46 +/- 12 (SD) years, 23 patients in age from 60 to 69 years (group II--mean 64 +/- 3 years), 33 patients in age from 70 to 79 years (group III--mean 75 +/- 3 years), 26 patients in age from 80 to 92 years (group IV--mean 84 +/- 4 years). In all participants oral glucose tolerance test (75 g) and the i.v. glucagon test (1 mg) were carried out and blood glucose, serum insulin (IRI) and C-peptide (CP) were measured. Hepatic clearance of insulin was calculated from the serum CP/IRI ratio. With advanced age the increase in fasting glycaemia (group I 4.25 +/- 0.6, group IV 4.7 +/- 0.5 mM, p = 0.02) and after applied stimuli, and a decrease in fasting (group I 0.6 +/- 0.2, group IV 0.35 +/- 0.13 nM, p < 0.05) and stimulated serum CP with no differences in serum IRI concentrations between groups was observed. Consequently the serum CP/IRI ratio decreased from 10 +/- 3.8 in group I to 5.4 +/- 1.7 in group IV (p < 0.05) indicating reduced insulin clearance in liver, probably as a compensatory adaptation to the deterioration of B cell secretory activity.
Pol Arch Med Wewn 1997 Feb
PMID:[The effect of age on glucose tolerance and B cell secretion]. 931 59


<< Previous 1 2 3 4 5 6 7 Next >>